autologous dendritic cell vaccine + sargramostim

A patient-specific combination immunotherapy consisting of an autologous dendritic cell vaccine formulated with the cytokine adjuvant sargramostim (granulocyte-macrophage colony-stimulating factor, GM-CSF) at the time of each injection. The autologous dendritic cell component is manufactured ex vivo from the patient’s monocytes and loaded with tumor-derived antigens (commonly whole-tumor lysate or antigens from self-renewing autologous tumor cells), then administered to elicit tumor-specific T cell responses. Sargramostim at the injection site serves as a local immunostimulatory adjuvant that recruits and activates antigen-presenting cells, enhancing vaccine-induced TH1/TH17-biased cellular immunity. Clinical experience in melanoma, glioblastoma, ovarian, hepatocellular, renal cell cancer and colorectal cancer indicates the approach is generally well tolerated and can induce immune responses, with signals of clinical activity in selected settings; however, it is investigational and not approved as a standardized product.

Other names

autologous DC vaccine + GM-CSFDC-ATA + GM-CSFautologous dendritic cells loaded with autologous tumor antigens + GM-CSFautologous dendritic cell cancer vaccine + sargramostim